Just read the report. Impressive clinical trials results.
Key Highlights:
• Travelan® shigellosis challenge studies in non-human primates successfully completed
• Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treatedanimals compared to placebo and demonstrated a significant clinical benefit
• Prophylactic administration of Travelan® may provide an effective prevention alternative toantibiotics for gastrointestinal infections in humans
• Three new Shigella specific anti-microbial therapeutics under preclinical evaluation
• A preventative treatment that protects against enteric diseases, specifically Shigella, is a highpriority objective for the US Army
Ann: US DoD Reports Results from Travelan Shigellosis Study, page-2
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.93M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $1.158K | 11.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9352 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 251204 | 4 |
View Market Depth
| Last trade - 10.48am 27/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |